Is There a Relationship Between Use of Anti-Vascular Endothelial Growth Factor Agents and Atrophic Changes in Age-Related Macular Degeneration Patients?
View abstract on PubMed
Summary
This summary is machine-generated.Anti-vascular endothelial growth factor (VEGF) treatments for wet age-related macular degeneration (AMD) may increase geographic atrophy risk. This review examines the evidence linking anti-VEGF therapy to geographic atrophy progression in AMD patients.
Area Of Science
- Ophthalmology
- Retinal Diseases
- Neovascular AMD Treatment
Background
- Age-related macular degeneration (AMD) with choroidal neovascularization (CNV) is effectively managed with anti-vascular endothelial growth factor (VEGF) therapies.
- There is emerging concern that anti-VEGF treatment might accelerate the development of geographic atrophy (GA).
Purpose Of The Study
- To review and discuss the current evidence regarding the association between anti-VEGF therapy and the progression of geographic atrophy in neovascular AMD.
Main Methods
- Literature review of studies investigating the effects of anti-VEGF agents on GA development and progression.
- Analysis of clinical trial data and observational studies.
Main Results
- Evidence suggests a potential link between anti-VEGF treatment and increased GA development.
- Direct causal proof remains elusive, necessitating further investigation.
Conclusions
- While anti-VEGF therapy is crucial for neovascular AMD, its potential role in GA progression requires careful consideration and further research.
- Understanding this association is vital for optimizing long-term AMD management strategies.